FibroGen, Inc. (0IL8.L)

USD 0.27

(-5.91%)

Long Term Debt Summary of FibroGen, Inc.

  • FibroGen, Inc.'s latest annual long term debt in 2023 was 89.69 Million USD , up 12.69% from previous year.
  • FibroGen, Inc.'s latest quarterly long term debt in 2024 Q1 was 89.65 Million USD , down -0.04% from previous quarter.
  • FibroGen, Inc. reported annual long term debt of 79.59 Million USD in 2022, down -10.35% from previous year.
  • FibroGen, Inc. reported annual long term debt of 88.77 Million USD in 2021, up 249.65% from previous year.
  • FibroGen, Inc. reported quarterly long term debt of 89.65 Million USD for 2024 Q1, down -0.04% from previous quarter.
  • FibroGen, Inc. reported quarterly long term debt of 145.22 Million USD for 2023 Q2, up 88.88% from previous quarter.

Annual Long Term Debt Chart of FibroGen, Inc. (2023 - 2012)

Historical Annual Long Term Debt of FibroGen, Inc. (2023 - 2012)

Year Long Term Debt Long Term Debt Growth
2023 89.69 Million USD 12.69%
2022 79.59 Million USD -10.35%
2021 88.77 Million USD 249.65%
2020 25.39 Million USD -34.48%
2019 38.75 Million USD -60.12%
2018 97.15 Million USD -0.62%
2017 97.76 Million USD 0.42%
2016 97.35 Million USD 0.32%
2015 97.04 Million USD 0.23%
2014 96.81 Million USD 0.43%
2013 96.4 Million USD 4.22%
2012 92.49 Million USD 0.0%

Peer Long Term Debt Comparison of FibroGen, Inc.

Name Long Term Debt Long Term Debt Difference
uniQure N.V. 130.06 Million USD 31.037%
Agios Pharmaceuticals, Inc. 56.98 Million USD -57.396%
Amicus Therapeutics, Inc. 387.85 Million USD 76.874%
Atara Biotherapeutics, Inc. 45.69 Million USD -96.304%
bluebird bio, Inc. 224.41 Million USD 60.031%
Cara Therapeutics, Inc. 37.07 Million USD -141.908%
Imunon, Inc. 1.13 Million USD -7773.041%
Editas Medicine, Inc. 24.37 Million USD -268.033%
IQVIA Holdings Inc. 12.95 Billion USD 99.308%
Mettler-Toledo International Inc. 1.97 Billion USD 95.46%
Myriad Genetics, Inc. 130.9 Million USD 31.477%
Neurocrine Biosciences, Inc. 258.3 Million USD 65.274%
Supernus Pharmaceuticals, Inc. 33.19 Million USD -170.204%
Verastem, Inc. 40.08 Million USD -123.761%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 98.885%
Waters Corporation 2.3 Billion USD 96.109%
Thermo Fisher Scientific Inc. 31.3 Billion USD 99.714%
Biogen Inc. 7.18 Billion USD 98.752%
Nektar Therapeutics 112.62 Million USD 20.358%
Perrigo Company plc 3.63 Billion USD 97.531%
Dynavax Technologies Corporation 252.41 Million USD 64.465%
Illumina, Inc. 1.48 Billion USD 93.976%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD -2669.596%
Iovance Biotherapeutics, Inc. 1 Million USD -8869.7%
Heron Therapeutics, Inc. 173.75 Million USD 48.377%
Unity Biotechnology, Inc. 23.53 Million USD -281.057%
BioMarin Pharmaceutical Inc. 593.09 Million USD 84.876%
Sangamo Therapeutics, Inc. 33.51 Million USD -167.632%
Evolus, Inc. 120.35 Million USD 25.475%
Adicet Bio, Inc. 17.7 Million USD -406.677%
Aclaris Therapeutics, Inc. 3.07 Million USD -2817.925%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 96.681%
Esperion Therapeutics, Inc. 501.54 Million USD 82.116%
Agilent Technologies, Inc. 2.73 Billion USD 96.72%
OPKO Health, Inc. 222.03 Million USD 59.602%
Homology Medicines, Inc. 43.17 Million USD -107.747%
Geron Corporation 35.05 Million USD -155.904%
Alnylam Pharmaceuticals, Inc. 2.34 Billion USD 96.172%
Exelixis, Inc. 189.94 Million USD 52.777%
Viking Therapeutics, Inc. 936 Thousand USD -9483.013%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 96.74 Million USD 7.287%
Zoetis Inc. 6.56 Billion USD 98.634%
Axsome Therapeutics, Inc. 178.07 Million USD 49.628%
Abeona Therapeutics Inc. 4.4 Million USD -1937.642%
Vertex Pharmaceuticals Incorporated 724.7 Million USD 87.623%
Kala Pharmaceuticals, Inc. 34.19 Million USD -162.349%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD 93.595%
Sarepta Therapeutics, Inc. 1.13 Billion USD 92.08%
Corcept Therapeutics Incorporated - USD -Infinity%
Halozyme Therapeutics, Inc. 1.49 Billion USD 94.017%
Blueprint Medicines Corporation 610.96 Million USD 85.319%
Insmed Incorporated 1.19 Billion USD 92.484%
TG Therapeutics, Inc. 100.11 Million USD 10.409%
Incyte Corporation 29.16 Million USD -207.582%
Emergent BioSolutions Inc. 446.5 Million USD 79.911%